Skip to main content

Pharma News

Pharma Courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • In 2019, over 70 percent antibiotics used in India were unapproved

    ​An eye opening study published in Lancet which highlights, India consumed 72.7 percent of unapproved antibiotics products in 2019. India has also consumed 48.7 percent of Fixed Dose Combinations discouraged by the WHO.

  • Cipla and Dr Reddys Lab receives FDA nod for Cancer medicine

    Cipla and Dr Reddys Lab receives FDA nod for marketing of generic version of REVLIMID (lenalidomide) Capsules. Both companies have received final approval of its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsules.

    With this volume-limited launch, Dr. Reddy’s Lab is eligible for first-to- market, 180 days of generic drug exclusivity for Lenalidomide Capsules in 2.5 mg and 20 mg strengths.

  • Toxin discovered that kills bacteria in unprecedented ways

    Researchers at McMaster University have discovered a previously unknown bacteria-killing toxin that could pave the way for a new generation of antibiotics.

    The study, led by John Whitney at the Michael G. DeGroote Institute for Infectious Disease Research, shows that the bacterial pathogen Pseudomonas aeruginosa, known to cause hospital-acquired infections such as pneumonia, secretes a toxin that has evolved to kill other species of bacteria.

  • Myocarditis after COVID-19 vaccines remain rare

    A new study from Israel found that the risk of developing myocarditis among males ages 16 to 19 years was about 1 in 15,000 after third dose of the Pfizer-BioNTech COVID-19 vaccine, and the cases were rare and mild, according to new research published today in the American Heart Association’s flagship journal Circulation.

  • Forxiga approved in China for CKD

    AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in China to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death and hospitalisation for heart failure (hHF) in adults with chronic kidney disease (CKD) at risk of progression with and without type-2 diabetes (T2D).

  • Lupin and DKSH inks to market five biosimilar candidates in Philippines

    Lupin and DKSH have signed an exclusive license and supply agreement to commercialize five of Alvotechs proposed biosimilars in the Philippines. The biosimilars planned under this agreement include biosimilar Prolia, Xgeva, Simponi, and Eylea as well as two undisclosed proposed biosimilars for immunology and oncology.

  • First intra nasal COVID-19 vaccine approved in India

    ​​CDSCO has approved a recombinant nasal vaccine for COVID-19 for restricted use in emergency situations.It is a recombinant replication deficient adenovirus vectored vaccine with a prefusion stabilised spike protein.

    Dr Mansukh Mandaviya Minister of Health and Family Welfare informed today that Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by CDSCO for primary immunization against COVID-19 in 18 plus age group for restricted use in emergency situation.

  • Inflation reduction act will cut Healthcare costs in USA

    ​With inflation reduction act, Medicare finally having the power to negotiate prescription drug prices with pharmaceutical industries which will affect millions of Americans across all 50 states and the District of Columbia

    It will lead to prescription drug costs capped at USD 2,000 annually in Medicare, and will save hundreds of dollars per year on health insurance premiums because of the law.

  • Centre approves of three more Bulk Drug Parks

    The Department of Pharmaceuticals has conveyed in-principle approval to the proposals of the three States Viz, Himachal Pradesh, Gujarat and Andhra Pradesh under the Scheme for Promotion of Bulk Drug Parks, a key initiative to support the Bulk Drugs manufacturing in the country.

  • FIrst AI enabled Cath lab launched by Wipro GE Healthcare

    GE Healthcare, a leading global medical technology, diagnostics and digital solutions innovator, has announced the launch of its first Made in India, AI-powered Cath lab - Optima IGS 320 to advance cardiac care in India.

Subscribe to Pharma News